• Merck reported Phase 3 KEYNOTE-B15 results supporting perioperative Keytruda with Padcev in resectable muscle-invasive bladder cancer.
• Results were already reported in the CHMP briefing; no future scientific meeting presentation was specified.
• Trial showed fewer disease events and longer survival versus standard neoadjuvant chemotherapy followed by surgery.
• EU regulators issued a positive CHMP opinion; European Commission decision expected in Q4 2026.
• U.S. regulators cleared the regimen in July 2026, positioning it as a key growth driver across earlier-stage bladder cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917438970) on September 18, 2026, and is solely responsible for the information contained therein.